Clin2
NCT02479698Possibly a fitRecruiting

Immune cells for BK or JC virus infections

Acquired Immunodeficiency SyndromeBK Virus InfectionHuman Immunodeficiency VirusJC Virus InfectionMalignant NeoplasmMerkel Cell CarcinomaMerkel Cell Polyomavirus InfectionViral Encephalitis

Part of Brain & nervous system, Cancer, Immune system & allergy, Infections clinical trials.

This trial tests a treatment using special immune cells (called cytotoxic T lymphocytes) to fight BK or JC virus infections in people with weakened immune systems, such as cancer patients or organ transplant recipients. It may help control the virus and reduce related complications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
Any age
Study type
Interventional

Who can take part

  • You are at least 2 years old.
  • You have a weakened immune system due to a condition like cancer, HIV/AIDS, or an organ transplant, or you have a JC virus brain infection (PML).
  • You have a BK or JC virus infection confirmed by blood, urine, or tissue tests.
  • If you are taking steroids, your dose must be 6 mg or less of prednisone (or equivalent) per day.
  • You cannot have certain treatments (like ATG, donor lymphocyte infusion, or alemtuzumab) within the past 14–28 days.
  • You do not have uncontrolled infections or severe graft-versus-host disease (GVHD) if you had a transplant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05264259Recruiting
Monoclonal antibodies for BK virus infection

This study tests a new treatment using lab-made antibodies to treat BK virus infection. It may help by controlling the virus in adults who already test BK positive.

Strasbourg
NCT07503561Not yet recruiting· Phase 2
Study of New Drug for BK Virus in Kidney Transplant

This study tests a new medicine (AIC468) to see if it can help clear BK virus from the blood of people who have recently had a kidney transplant. Participants will receive either the study drug or a placebo (a dummy pill) to compare outcomes.

NCT05183490Recruiting· Phase 1
Cell therapy for repeated viral infections after transplant

This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.

New York, New York
NCT06926894Recruiting· Phase 1
A cell therapy for viral infections in children and young adults

This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.

New York, New York
NCT04013802Recruiting· Phase 1
Multivirus T-cell treatment for EBV, CMV, adenovirus, and BK after transplant

This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.

Houston, Texas
NCT04197596Recruiting· Phase 1/Phase 2
BK infection immune-cell treatment after transplant or weak immunity

This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.

San Francisco, California

Hear when a new Acquired Immunodeficiency Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.